Evidence map›Paper›PMID 30003151›Full record

ArticleHeliyon2018

Tumor-targeting

Kentaro Miyake, Kei Kawaguchi, Masuyo Miyake, Ming Zhao, Tasuku Kiyuna, Kentaro Igarashi, Zhiying Zhang, Takashi Murakami, Yunfeng Li, Scott D Nelson and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Culture of attenuatedHuman vaccines & immunotherapeutics · 2023
    Article
  4. Intratumoral injection of schwannoma with attenuatedProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  5. Article
  6. Review
  7. Journal of Cancer · 2019
    Review
  8. The Combination of Tumor-targetingIn vivo (Athens, Greece)
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kentaro MiyakeAntiCancer Inc., San Diego, CA, USA.
Kei KawaguchiAntiCancer Inc., San Diego, CA, USA.
Masuyo MiyakeAntiCancer Inc., San Diego, CA, USA.
Ming ZhaoAntiCancer Inc., San Diego, CA, USA.
Tasuku KiyunaAntiCancer Inc., San Diego, CA, USA.
Kentaro IgarashiAntiCancer Inc., San Diego, CA, USA.
Zhiying ZhangAntiCancer Inc., San Diego, CA, USA.
Takashi MurakamiDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yunfeng LiDeptartment of Pathology, University of California, Los Angeles, CA, USA.
Scott D NelsonDeptartment of Pathology, University of California, Los Angeles, CA, USA.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, USA.
Irmina ElliottDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Yukihiko HiroshimaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masashi MomiyamaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Ryusei MatsuyamaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takashi ChishimaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Shree Ram SinghBasic Research Laboratory, National Cancer Institute, Frederick, MD, USA.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer Inc., San Diego, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel efficacious therapy. The aim of our study was to evaluate the effectiveness of tumor-targeting

Indexed as

BiochemistryCancer researchGeneticsMicrobiology

Identifiers

PMID30003151
PMCPMC6040627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.